This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hepatic disease				
Nonalcoholic steatohepatitis (NASH)	Transmembrane 6 superfamily member 2 (TM6SF2)	<p>Patient sample and cell culture studies suggest increasing TM6SF2 levels could help treat NASH. In 206 human liver samples, the NASH-associated rs10401969 SNP correlated with decreased expression of <i>TM6SF2</i> and low plasma triglyceride concentrations. In two human hepatic cell lines, siRNA against <i>TM6SF2</i> decreased secretion of triglyceride-rich lipoproteins and increased the number and size of lipid droplets compared with control siRNA. In <i>TM6SF2</i>-overexpressing human hepatic cell lines, lipid droplet size was smaller than that in cells with normal <i>TM6SF2</i> expression. Next steps could include identifying strategies to increase TM6SF2 levels.</p> <p><i>SciBX</i> 7(26); doi:10.1038/scibx.2014.770 Published online July 10, 2014</p>	Patent and licensing status unavailable	<p>Mahdessian, H. <i>et al. Proc. Natl. Acad. Sci. USA</i>; Published online July 4, 2014; doi:10.1073/pnas.1323785111 Contact: Ferdinand van't Hooft, Karolinska Institute, Stockholm, Sweden e-mail: ferdinand.vant.hooft@ki.se</p>